Cited by 280Metabolism and Genetic DisordersAmino Acid Enzymes and MetabolismBiochemical Acid Research Studies

Maple syrup urine disease: mechanisms and management

Open access
Blackburn, Patrick, Gass, Jennifer, Pinto e Vairo, Filippo, Farnham, Kristen, Atwal, Herjot, Macklin, Sarah, Klee, Eric, Atwal, Paldeep·2017·The Application of Clinical Genetics

Abstract

Maple syrup urine disease (MSUD) is an inborn error of metabolism caused by defects in the branched-chain α-ketoacid dehydrogenase complex, which results in elevations of the branched-chain amino acids (BCAAs) in plasma, α-ketoacids in urine, and production of the pathognomonic disease marker, alloisoleucine. The disorder varies in severity and the clinical spectrum is quite broad with five recognized clinical variants that have no known association with genotype. The classic presentation occurs in the neonatal period with developmental delay, failure to thrive, feeding difficulties, and maple syrup odor in the cerumen and urine, and can lead to irreversible neurological complications, including stereotypical movements, metabolic decompensation, and death if left untreated. Treatment consists of dietary restriction of BCAAs and close metabolic monitoring. Clinical outcomes are generally good in patients where treatment is initiated early. Newborn screening for MSUD is now commonplace in the United States and is included on the Recommended Uniform Screening Panel (RUSP). We review this disorder including its presentation, screening and clinical diagnosis, treatment, and other relevant aspects pertaining to the care of patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/tacg.s125962

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BCAA catabolism is repressed in maple syrup urine disease, which is caused by mutations to branched-chain keto acid dehydrogenase and causes dysfunction of immune cells, skeletal muscle and the central nervous system.

    “BCAA catabolism is repressed in maple syrup urine disease, which is caused by mutations to branched-chain keto acid dehydrogenase (BCKDH) and causes dysfunction of immune cells, skeletal muscle and the central nervous system.48”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 53 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [50]Strauss KA Wardley B Robinson D Classical maple syrup urine disease and brain development: Principles of management and formula design Mol Genet Metab 2010 99 4 333 345 20061171 PMC3671925

Cited by

Sorted by citations

Authors
Blackburn, P., Gass, J., Pinto e Vairo, F., Farnham, K., Atwal, H., Macklin, S., Klee, E., & Atwal, P.
Affiliations
  • Mayo Clinic in Florida (US)
  • Mayo Clinic (US)
Corresponding author
Atwal, Paldeep
Venue
The Application of Clinical Genetics
Published
2017-09
Volume
Volume 10
Pages
57-66
ISSN
1178-704X (ISSN-L)
OpenAlex
W2752428554
Cited by
280
References
53
Citations by year
2026: 26 · 2025: 38 · 2024: 55 · 2023: 32 · 2022: 31 · 2021: 42 · 2020: 27 · 2019: 17 · 2018: 10 · 2015: 1 · 2012: 1
FWCI
1.93
Type
journal article
Language
en
Open access
Locations
  • The Application of Clinical Genetics (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
  • Mayo Clinic
  • Center for Individualized Medicine, Mayo Clinic
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Biochemical Acid Research Studies
Keywords
maple syrup urine disease, branched-chain amino acids, inborn errors of metabolism, alloisoleucine, clinical variants, neonatal presentation, neurological complications, dietary restriction, metabolic monitoring, newborn screening

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review